首页> 外文期刊>Journal of cellular biochemistry. >5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
【24h】

5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.

机译:5alpha-androstane-3alpha,17beta-diol通过不依赖于雄激素受体的信号传导途径支持人类前列腺癌细胞的生存和增殖:不依赖于雄激素的前列腺癌的进展。

获取原文
获取原文并翻译 | 示例
       

摘要

Androgen and androgen receptor (AR) are involved in growth of normal prostate and development of prostatic diseases including prostate cancer. Androgen deprivation therapy is used for treating advanced prostate cancer. This therapeutic approach focuses on suppressing the accumulation of potent androgens, testosterone and 5alpha-dihydrotestosterone (5alpha-DHT), or inactivating the AR. Unfortunately, the majority of patients with prostate cancer eventually advance to androgen-independent states and no longer respond to the therapy. In addition to the potent androgens, 5alpha-androstane-3alpha,17beta-diol (3alpha-diol), reduced from 5alpha-DHT through 3alpha-hydroxysteroid dehydrogenases (3alpha-HSDs), activated signaling may represent a novel pathway responsible for the progression to androgen-independent prostate cancer. Androgen sensitive human prostate cancer LNCaP cells were used to compare 5alpha-DHT and 3alpha-diol activated androgenic effects. In contrast to 5alpha-DHT, 3alpha-diol regulated unique patterns of beta-catenin and Akt expression as well as Akt phosphorylation in parental and in AR-silenced LNCaP cells. More significantly, 3alpha-diol, but not 5alpha-DHT, supported AR-silenced LNCaP cells and AR negative prostate cancer PC-3 cell proliferation. 3alpha-diol-activated androgenic effects in prostate cells cannot be attributed to the accumulation of 5alpha-DHT, since 5alpha-DHT formation was not detected following 3alpha-diol administration. Potential accumulation of 3alpha-diol, as a result of elevated 3alpha-HSD expression in cancerous prostate, may continue to support prostate cancer growth in the presence of androgen deprivation. Future therapeutic strategies for treating advanced prostate cancer might need to target reductive 3alpha-HSD to block intraprostatic 3alpha-diol accumulation.
机译:雄激素和雄激素受体(AR)参与正常前列腺的生长和包括前列腺癌在内的前列腺疾病的发展。雄激素剥夺疗法用于治疗晚期前列腺癌。这种治疗方法的重点是抑制强效雄激素,睾丸激素和5α-二氢睾丸激素(5alpha-DHT)的积累或使AR失活。不幸的是,大多数前列腺癌患者最终会发展为雄激素非依赖性状态,并且不再对治疗产生反应。除了有效的雄激素,5alpha-androstane-3alpha,17beta-diol(3alpha-diol)(通过3alpha-羟基类固醇脱氢酶(3alpha-HSDs)从5alpha-DHT还原)之外,活化的信号传导可能代表负责向非雄激素依赖性前列腺癌。雄激素敏感的人类前列腺癌LNCaP细胞用于比较5alpha-DHT和3alpha-二醇激活的雄激素作用。与5alpha-DHT相反,在亲本和AR沉默的LNCaP细胞中,3alpha-二醇调节β-catenin和Akt表达以及Akt磷酸化的独特模式。更重要的是,3alpha二醇而不是5alpha-DHT支持AR沉默的LNCaP细胞和AR阴性前列腺癌PC-3细胞增殖。前列腺细胞中3α-二醇激活的雄激素作用不能归因于5α-DHT的积累,因为在3α-二醇给药后未检测到5α-DHT的形成。在癌性前列腺中3α-HSD表达升高的结果是3α-二醇的潜在积累可能会继续支持雄激素剥夺时前列腺癌的生长。未来治疗晚期前列腺癌的治疗策略可能需要靶向还原性3α-HSD,以阻断前列腺内3α-二醇的积累。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号